Abstract: This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.

Abstract: Provided herein are substituted hydrazone compounds useful as inhibitors of DEPTOR. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted hydrazone compounds.